GLOW Blend
A cosmetic-first three-peptide blend of GHK-Cu, BPC-157, and TB-500, weighted heavily toward GHK-Cu for skin, hair, and post-procedure recovery.
GLOW is a compounded peptide blend combining GHK-Cu, BPC-157, and TB-500 in a single vial, typically loaded at 70 mg total with GHK-Cu dominant (a common ratio is 50:10:10). It is essentially KLOW without the anti-inflammatory KPV component, repositioned toward aesthetics and tissue repair rather than gut and immune support. GHK-Cu carries most of the evidence behind the blend; BPC-157 and TB-500 broaden the use case toward connective-tissue repair and post-procedure recovery. No controlled trial exists on the blend itself.
Class
Compounded three-peptide blend (GHK-Cu + BPC-157 + TB-500)
Half-life
Varies by component
Routes
Subcutaneous injection, Dissolving strip (some vendor formats)
Category
Healing & Recovery
Researched benefits
What it's studied for
Skin quality and collagen remodeling
The GHK-Cu component drives the cosmetic story, stimulating collagen and elastin synthesis and broad gene-expression modulation. GHK-Cu has 50-plus published studies and active delivery-science research, making it the evidence-carrying component of the blend.
Post-procedure recovery
The consistent reported use case is recovery after laser, microneedling, or chemical peel, with users describing skin-quality improvements within roughly 6 to 8 weeks. This is the blend's core positioning.
Hair density
Users report improved hair density when GLOW is paired with scalp microneedling, an application driven mainly by the GHK-Cu component's signaling effects.
Connective-tissue and wound repair
BPC-157 contributes angiogenesis, localized wound healing, and tendon support, broadening the blend beyond skin toward minor connective-tissue strain.
Cellular migration and tissue remodeling
TB-500 adds cell migration and actin-cytoskeleton remodeling, supporting systemic tissue repair alongside the localized action of GHK-Cu and BPC-157.
Mechanism
How it works
GLOW combines three peptides that act on complementary layers of skin and connective tissue. GHK-Cu, the dominant component, stimulates collagen and elastin synthesis and modulates a wide set of genes involved in skin remodeling and repair. It is the component that carries the blend's evidence base, with more than 50 published studies and ongoing delivery-science research.
BPC-157 contributes localized wound healing, anti-inflammatory action, and angiogenesis, supporting tendon and connective-tissue repair. TB-500 (whose vials may contain the ~889 Da fragment or full thymosin beta-4 at ~4963 Da depending on source) adds cell migration and actin-cytoskeleton remodeling to drive systemic tissue repair.
On paper the blend covers structural, cellular, and mechanical aspects of skin and connective tissue simultaneously: collagen and elastin signaling from GHK-Cu, angiogenesis and wound repair from BPC-157, and migration and remodeling from TB-500. This makes the combination mechanistically broader than GHK-Cu alone.
The mechanistic rationale is coherent but the blend is formally untested as a unit. No head-to-head trial compares GLOW against GHK-Cu alone or against a BPC-157 + TB-500 pairing, and several users report that the additional benefit over solo GHK-Cu is difficult to perceive.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
GLOW is supplied as a lyophilized multi-peptide vial (commonly 70 mg total) reconstituted with bacteriostatic water; the exact volume and per-injection dose depend on the vendor's ratio, so verify the mass of each component on the Certificate of Analysis before use.
Standard (as marketed)
- Dose
- Per manufacturer protocol from a 70 mg vial at a GHK-Cu-dominant ratio (commonly 50:10:10)
- Frequency
- Per manufacturer protocol
- Timing
- Often timed around a cosmetic procedure
- Duration
- Skin-quality changes reported over roughly 6-8 weeks
- Route
- Subcutaneous injection
GLOW is a compounded blend with no FDA approval and no controlled clinical dosing data; formulations and ratios vary by source and no standard exists.
- No standardized formulation exists; disclosed ratios include 50/10/10, 35/10/5, and 70 mg total, so read the component masses on the COA rather than assuming a fixed dose.
- The consistent reported application is post-procedure recovery (laser, microneedling, peel); hair-density reports pair GLOW with scalp microneedling.
- Because the blend has no controlled trials, dosing should be treated as extrapolated from the individual components, not validated for the combination.
Combinations
Stacking & blends
GLOW (the blend itself)
Skin quality, hair density, and post-procedure recovery
GHK-Cu supplies collagen and elastin signaling, BPC-157 adds angiogenesis and localized wound repair, and TB-500 contributes cell migration and remodeling, covering structural, cellular, and mechanical aspects of skin and connective tissue at once.
GLOW vs KLOW selection
Choosing between the cosmetic and gut-inflammation versions
KLOW adds KPV for the mucosal/gut and systemic-inflammation arm; for skin, hair, and post-procedure recovery GLOW covers the use case, while a gut or systemic-inflammation story favors KLOW.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Known allergy to any blend component
- Active skin infection at the injection site
- Pregnancy or breastfeeding
Component-level safety profiles are relatively clean, but the blend itself has no clinical trial data and no independent blend-specific safety record. Interaction data is compiled from published research and community reports and may not be exhaustive.
FAQ
GLOW Blend — common questions
What is GLOW?
GLOW is a compounded peptide blend containing GHK-Cu, BPC-157, and TB-500 in a single vial. It is essentially KLOW minus the KPV component, marketed by peptide clinics with a focus on aesthetic and tissue-repair applications rather than gut or inflammation effects. Note that the TB-500 component may be the ~889 Da fragment or full thymosin beta-4 at ~4963 Da depending on the vial, so check the COA.
What does GLOW do?
It combines three complementary mechanisms: GHK-Cu stimulates collagen synthesis and skin remodeling, BPC-157 supports localized wound healing and anti-inflammatory effects, and TB-500 drives systemic tissue repair. It is positioned as the aesthetic-forward version of the KLOW blend, oriented toward skin quality and recovery.
How does GLOW differ from GHK-Cu alone?
GHK-Cu is doing most of the work and carries the evidence, with 50-plus studies behind it. BPC-157 and TB-500 broaden the use case toward connective-tissue repair rather than raising the proof standard. There is no head-to-head trial of GLOW against GHK-Cu alone, and several users describe the additional benefit as hard to perceive.
How is GLOW typically administered?
GLOW is a compounded subcutaneous blend with no FDA approval and no controlled clinical dosing data. Formulations vary by source, and there is no standardized dose or protocol; the per-injection amount depends on the vendor's ratio, commonly built from a 70 mg vial with GHK-Cu dominant.
What are the side effects of GLOW?
Reports are generally clean, with occasional injection-site reactions and transient blue-green coloring at the injection site from the GHK-Cu copper component. The blend itself has no clinical trial data.
Is GLOW FDA approved?
No. GLOW is a compounded peptide blend and none of its components are FDA-approved for the combined indication. As of April 2026 the FDA removed BPC-157, TB-500, and injectable GHK-Cu from the 503A category 2 list, with PCAC reviews scheduled through early 2027.
Should I choose GLOW or KLOW?
If the use case is skin, hair, and post-procedure recovery, GLOW covers it. If there is a gut component or systemic-inflammation story, KLOW adds KPV for that additional pathway. Neither blend has a controlled trial behind the package.
